Genetically Engineered Mosquitoes Research Authorization Application
This webpage was last updated on May 11, 2023
In May 2023, Oxitec voluntarily withdrew its research authorization application to test the use of genetically engineered mosquitoes in California. DPR did not issue a decision on the application. For more information on Oxitec’s withdrawal and future plans for research in California, see their letter, PDF.
The company applied for a research authorization from the department in March 2022 to release and study the use of genetically engineered Aedes aegypti mosquitoes to reduce the current Aedes aegypti mosquito population in Tulare County, California.
DPR must approve a research authorization application before an unregistered pesticide can be field tested in the state. There is no pending research authorization or active application for the study of genetically engineered mosquitoes in California at this time.
Where can I review Oxitec’s previously submitted research authorization application received by DPR?
The department has posted on its website the following documents related to Oxitec’s research authorization application. This research authorization application is no longer in review by the department.
- Application for research authorization from Oxitec, Ltd
- U.S. EPA documents submitted to DPR by Oxitec related to its research authorization application
- Human Health and Environmental Risk Assessment of OX5034 Aedes aegypti Containing Tetracycline-Repressible Transactivator Protein Variant (tTAV-OX5034, New Active Ingredient), DsRed2-OX5034 Protein (new inert ingredient), and the Genetic Material Necessary (Vector pOX5034) for Production of the Proteins in vivo. Data and Information Provided in Support of an Extension and Amendment to a FIFRA Section 5 Experimental Use Permit for Testing in Florida and California
- Review of Section G (dated February 18, 2022) for an Experimental Use Permit (EUP) 93167-EUP-2 to Test OX5034 Aedes aegypti Mosquitoes in California and Extend the Existing EUP in Florida
- Section G OX5034 Aedes Aegypti: Proposed Field Trial Protocol for an Experimental Use Permit
- EPA’s Response to Comments Received on the August 31, 2021, Notice for an Experimental Use Permit Amendment for OX5034 Aedes aegypti Mosquitoes Expressing Tetracycline Trans Activator Variant (tTAV-OX5034) Protein
- EPA’s Response to Comments - OX5034 EUP Amendment and Extension Request
- Experimental Use Permit Amended for 93167-EUP-2 to Allow Releases of OX5034 Aedes aegypti in Florida and California
- OX5034 Aedes aegypti: Species-Specific Larvicide Effective in Killing Female Aedes Aegypti Mosquito Larvae (US EPA EUP Label)